<DOC>
	<DOCNO>NCT00261014</DOCNO>
	<brief_summary>The purpose study develop way predict patient diagnosed idiopathic blood clot safely stop warfarin therapy six month . We use patient characteristic , blood test result image test result identify patient low risk develop new blood clot warfarin stop .</brief_summary>
	<brief_title>Understanding Risk Factors Involved Developing Second Blood Clot .</brief_title>
	<detailed_description>The risk recurrent VTE patient idiopathic VTE subsequent three six month oral anticoagulant therapy remain high ( 5-27 % per year ) . The risk recurrent VTE , however , likely high enough justify indefinite anticoagulation patient first idiopathic VTE due rate major bleed oral anticoagulant ( 2-6 % per year ) , inconvenience cost oral anticoagulant therapy , monitor oral anticoagulant therapy ( e.g . prescription cost , time work go lab test , park etc ) lifestyle limitation oral anticoagulant therapy ( avoidance certain physical activity , dietary restriction , avoidance pregnancy ) . Further , argue , perhaps anticoagulant therapy achieves delay recurrent VTE , recent editorial suggest , tailor approach required determine sub-groups require lifelong anticoagulation . A means stratify patient idiopathic VTE identify group low risk recurrent VTE could safely discontinue oral anticoagulant subsequent six month therapy would significant advance care patient .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>1 . Objectively proven ( previously describe ( 8 ) ) proximal idiopathic deep vein thrombosis pulmonary embolism . Idiopathic define VTE occur absence fracture , plaster cast , immobilization great 3 day general anesthetic last three month prior VTE diagnosis ; know deficiency antithrombin , protein C protein S ; malignancy last five year 2 . Patients treat initially minimum five day heparin low molecular weight heparin oral anticoagulant target intensity 2.0 3.0 recurrence subsequent six month . 3 . Patients currently oral anticoagulant 1 . Recurrent idiopathic VTE ( i.e . &amp; # 8805 ; 2 previous idiopathic VTE ) . Previous secondary VTE exclusion criterion ; 2 . Age &amp; lt ; 18 ; 3 . Known deficiency protein S , protein C antithrombin ; 4 . Known , persistently positive anticardiolipin antibody ( titer &amp; gt ; 30U/ml ) ; 5 . Known , persistently positive lupus anticoagulant ; 6 . Combined thrombophilic defect ( e.g . homozygous FVL PGM , compound heterozygous FVL PGM ) ; 7 . Refusal informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Recurrent</keyword>
	<keyword>Idiopathic</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Clinical Prediction Rule</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Risk Factors</keyword>
</DOC>